These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16952781)

  • 1. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study.
    Cingolani HE; Plastino JA; Escudero EM; Mangal B; Brown J; Pérez NG
    J Card Fail; 2006 Sep; 12(7):491-8. PubMed ID: 16952781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
    Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
    Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.
    Hare JM; Mangal B; Brown J; Fisher C; Freudenberger R; Colucci WS; Mann DL; Liu P; Givertz MM; Schwarz RP;
    J Am Coll Cardiol; 2008 Jun; 51(24):2301-9. PubMed ID: 18549913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy.
    Minhas KM; Saraiva RM; Schuleri KH; Lehrke S; Zheng M; Saliaris AP; Berry CE; Barouch LA; Vandegaer KM; Li D; Hare JM
    Circ Res; 2006 Feb; 98(2):271-9. PubMed ID: 16357304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure.
    Gao R; Zhang J; Cheng L; Wu X; Dong W; Yang X; Li T; Liu X; Xu Y; Li X; Zhou M
    J Am Coll Cardiol; 2010 May; 55(18):1907-14. PubMed ID: 20430261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preservation of cardiac contractility after long-term therapy with oxypurinol in post-ischemic heart failure in mice.
    Tan Z; Dai T; Zhong X; Tian Y; Leppo MK; Gao WD
    Eur J Pharmacol; 2009 Oct; 621(1-3):71-7. PubMed ID: 19737552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxipurinol: alloxanthine, Oxyprim, oxypurinol.
    Drugs R D; 2004; 5(3):171-5. PubMed ID: 15139781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
    Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.
    Palazzuoli A; Silverberg DS; Iovine F; Calabrò A; Campagna MS; Gallotta M; Nuti R
    Am Heart J; 2007 Oct; 154(4):645.e9-15. PubMed ID: 17892986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathy.
    Baldus S; Müllerleile K; Chumley P; Steven D; Rudolph V; Lund GK; Staude HJ; Stork A; Köster R; Kähler J; Weiss C; Münzel T; Meinertz T; Freeman BA; Heitzer T
    Free Radic Biol Med; 2006 Oct; 41(8):1282-8. PubMed ID: 17015175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.
    Dargie HJ; Hildebrandt PR; Riegger GA; McMurray JJ; McMorn SO; Roberts JN; Zambanini A; Wilding JP
    J Am Coll Cardiol; 2007 Apr; 49(16):1696-704. PubMed ID: 17448371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure.
    Mellin V; Isabelle M; Oudot A; Vergely-Vandriesse C; Monteil C; Di Meglio B; Henry JP; Dautreaux B; Rochette L; Thuillez C; Mulder P
    Eur Heart J; 2005 Aug; 26(15):1544-50. PubMed ID: 15872033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study.
    Yamada T; Node K; Mine T; Morita T; Kioka H; Tsukamoto Y; Tamaki S; Masuda M; Okuda K; Fukunami M
    Am Heart J; 2007 Jun; 153(6):1055.e1-8. PubMed ID: 17540209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The calcium channel blocker felodipine attenuates the positive hemodynamic effects of the beta-blocker metoprolol in severe dilated cardiomyopathy--a prospective, randomized, double-blind and placebo-controlled study with invasive hemodynamic assessment.
    Braun M; Edelmann F; Knapp M; Schön S; Schwencke C; Simonis G; Borst M; Weinbrenner C; Strasser RH
    Int J Cardiol; 2009 Feb; 132(2):248-56. PubMed ID: 18579230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy.
    Springer J; Tschirner A; Hartman K; von Haehling S; Anker SD; Doehner W
    Int J Cardiol; 2013 Oct; 168(4):3527-31. PubMed ID: 23751350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
    Krum H; Ashton E; Reid C; Kalff V; Rogers J; Amarena J; Singh B; Tonkin A
    J Card Fail; 2007 Feb; 13(1):1-7. PubMed ID: 17338996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story?
    Reyes AJ; Leary WP
    Cardiovasc Drugs Ther; 2005 Oct; 19(5):311-3. PubMed ID: 16382292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ongoing search for a stratified medicine approach in heart failure.
    Tang WH
    J Am Coll Cardiol; 2008 Jun; 51(24):2310-2. PubMed ID: 18549914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.